Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2014 4
2015 4
2016 2
2017 1
2018 4
2020 4
2021 2
2022 6
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. Kilian M, et al. Among authors: jung s. Cancer Cell. 2023 Feb 13;41(2):235-251.e9. doi: 10.1016/j.ccell.2022.12.007. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638785 Free article.
NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C, Kilian M, Chih YC, Kourtesakis A, Hoffmann DC, Boschert T, Koopmann P, Sanghvi K, De Roia A, Jung S, Jähne K, Day B, Shultz LD, Ratliff M, Harbottle R, Green EW, Will R, Wick W, Platten M, Bunse L. Krämer C, et al. Among authors: jung s. Neuro Oncol. 2024 Feb 2;26(2):266-278. doi: 10.1093/neuonc/noad172. Neuro Oncol. 2024. PMID: 37715782 Free PMC article.
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, Eichmüller SB, von Deimling A, Wick W, Sahm F, Platten M, Bunse L. Kilian M, et al. Among authors: jung s. Clin Cancer Res. 2022 Jan 15;28(2):378-389. doi: 10.1158/1078-0432.CCR-21-1881. Epub 2021 Nov 15. Clin Cancer Res. 2022. PMID: 34782365 Free PMC article.
Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: A randomized controlled trial.
Wollmer MA, Neumann I, Jung S, Bechinie A, Herrmann J, Müller A, Wohlmuth P, Fournier-Kaiser L, Sperling C, Peters L, Kneer J, Engel J, Jürgensen F, Schulze J, Nagel M, Prager W, Sinke C, Kahl KG, Karst M, Dulz B, Kruger THC. Wollmer MA, et al. Among authors: jung s. J Psychopharmacol. 2022 Feb;36(2):159-169. doi: 10.1177/02698811211069108. Epub 2022 Feb 1. J Psychopharmacol. 2022. PMID: 35102782 Clinical Trial.
Neuronal effects of glabellar botulinum toxin injections using a valenced inhibition task in borderline personality disorder.
Kruger THC, Schulze J, Bechinie A, Neumann I, Jung S, Sperling C, Engel J, Müller A, Kneer J, Kahl KG, Karst M, Herrmann J, Fournier-Kaiser L, Peters L, Jürgensen F, Nagel M, Prager W, Dulz B, Wohlmuth P, Heßelmann V, Sinke C, Wollmer MA. Kruger THC, et al. Among authors: jung s. Sci Rep. 2022 Aug 20;12(1):14197. doi: 10.1038/s41598-022-17509-0. Sci Rep. 2022. PMID: 35987909 Free PMC article. Clinical Trial.
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.
Lu KH, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L. Lu KH, et al. Among authors: jung s. Neurooncol Adv. 2022 Aug 31;4(1):vdac140. doi: 10.1093/noajnl/vdac140. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36196364 Free PMC article.
30 results